CA2155129A1 - Combinaisons d'inhibiteurs retroviraux - Google Patents

Combinaisons d'inhibiteurs retroviraux

Info

Publication number
CA2155129A1
CA2155129A1 CA2155129A CA2155129A CA2155129A1 CA 2155129 A1 CA2155129 A1 CA 2155129A1 CA 2155129 A CA2155129 A CA 2155129A CA 2155129 A CA2155129 A CA 2155129A CA 2155129 A1 CA2155129 A1 CA 2155129A1
Authority
CA
Canada
Prior art keywords
combinations
retroviral inhibitors
combination
retroviral
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2155129A
Other languages
English (en)
Other versions
CA2155129C (fr
Inventor
A. Stanley Tyms
Debra L. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2155129A1 publication Critical patent/CA2155129A1/fr
Application granted granted Critical
Publication of CA2155129C publication Critical patent/CA2155129C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La combinaison d'esters de castanospermine et d'analogues peptidiques courts peut être utilisée dans le traitement des infections rétrovirales. La combinaison peut être utilisée pour traiter le sida et le para-sida et d'autres maladies provoquées par le rétrovirus VIH ou autres virus connexes.
CA002155129A 1993-02-22 1994-01-18 Combinaisons d'inhibiteurs retroviraux Expired - Fee Related CA2155129C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9303518.6 1993-02-22
GB939303518A GB9303518D0 (en) 1993-02-22 1993-02-22 Combinations of retroviral inhibitors

Publications (2)

Publication Number Publication Date
CA2155129A1 true CA2155129A1 (fr) 1994-09-01
CA2155129C CA2155129C (fr) 1999-04-13

Family

ID=10730826

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155129A Expired - Fee Related CA2155129C (fr) 1993-02-22 1994-01-18 Combinaisons d'inhibiteurs retroviraux

Country Status (14)

Country Link
EP (1) EP0684836A1 (fr)
JP (1) JPH08509469A (fr)
KR (1) KR100293299B1 (fr)
CN (1) CN1118142A (fr)
AU (1) AU679497B2 (fr)
CA (1) CA2155129C (fr)
GB (1) GB9303518D0 (fr)
HU (1) HUT72493A (fr)
IL (1) IL108696A (fr)
MX (1) MXPA94001311A (fr)
NO (1) NO307738B1 (fr)
NZ (1) NZ261740A (fr)
WO (1) WO1994019008A1 (fr)
ZA (1) ZA941036B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889014A1 (fr) 2005-07-22 2007-01-26 Nextamp Sa Procede et dispositif de tatouage d'horodates, procede et dispositif de decodage d'horodates, applications et produits programmes d'ordinateur correspondants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3526015A1 (de) * 1985-07-20 1987-01-22 Philips Patentverwaltung Verfahren zum bestimmen der raeumlichen verteilung der streuquerschnitte fuer elastisch gestreute roentgenstrahlung und anordnung zur durchfuehrung des verfahrens
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4999146A (en) * 1990-02-12 1991-03-12 Thermax Wire Corp. Process for manufacture of low density polytetrofluoroethylene insulated cable
EP0565631B1 (fr) * 1991-01-02 1996-09-18 Merrell Pharmaceuticals Inc. Composes antiviraux

Also Published As

Publication number Publication date
NO953272D0 (no) 1995-08-21
IL108696A (en) 1999-06-20
AU6091894A (en) 1994-09-14
GB9303518D0 (en) 1993-04-07
MXPA94001311A (es) 2003-11-13
EP0684836A1 (fr) 1995-12-06
IL108696A0 (en) 1994-05-30
WO1994019008A1 (fr) 1994-09-01
HU9502451D0 (en) 1995-10-30
NZ261740A (en) 1996-10-28
CA2155129C (fr) 1999-04-13
NO307738B1 (no) 2000-05-22
HUT72493A (en) 1996-05-28
KR960700743A (ko) 1996-02-24
JPH08509469A (ja) 1996-10-08
ZA941036B (en) 1994-08-25
CN1118142A (zh) 1996-03-06
NO953272L (no) 1995-08-21
KR100293299B1 (ko) 2001-09-17
AU679497B2 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
WO1995033464A3 (fr) Combinaisons d'inhibiteurs de protease retrovirale
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
AU697681B2 (en) Retroviral protease inhibiting compounds
HK129093A (en) N-tert-butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl)isoquinoline-3-carboxamide & asparaginyl derivatives thereof
AU653972B2 (en) HIV protease inhibitors
AU2452288A (en) Nucleoside derivatives useful in treating retroviral infections
MY119031A (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
MY138860A (en) Hiv protease inhibitors.
RU95106823A (ru) Сукциноиламиногидроксиэтиламиносульфонамиды, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции способ лечения спида
AU9125191A (en) Retroviral protease inhibitors
AU6822990A (en) Hiv protease inhibitors useful for the treatment of aids
CA2075173A1 (fr) Composes et methodes pour inhiber le vih et les virus associes
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
AU667593B2 (en) Inhibitors of HIV protease useful for the treatment of AIDS
CA2168447A1 (fr) Composes et methodes pour l'inhibition du vih et de virus connexes
AU5252993A (en) Inhibitors of HIV protease useful for the treatment of AIDS
AU4135493A (en) Inhibitors of HIV protease useful for the treatment of AIDS
AU5491194A (en) Cytotoxic and antiviral compound
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
CA2285463A1 (fr) Therapie combinee des infections au vih
CA2155129A1 (fr) Combinaisons d'inhibiteurs retroviraux
EP0355409A3 (fr) L'utilisation d'un inhibiteur de prolylendopeptidase pour le traitement du SIDA
AU6592990A (en) Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones
HU9602158D0 (en) Macrocyclic difluorostatone derivatives useful as antiviral agents
WO1988008707A3 (fr) Derives de rubradirine pour le traitement de l'infection hiv

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20060118